# US 12,497,360 B2 · Crystalline 4-hydroxy-N,N-di-n-propyltryptammonium (4-HO-DPT) salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,497,360 B2
- Document ID: US12497360B2
- Status: Granted
- Kind: B2
- Application number: 18/430,845
- Filed: 2024-02-02
- Published: 2024-05-23
- Granted: 2025-12-16
- Earliest claimed: 2020-05-20
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. Chadeayne
- Web page: https://patentgrep.com/patent/US12497360B2

## CPC

- C07D 209/16: Tryptamines
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07C 57/15: Fumaric acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This disclosure relates to crystalline bis(4-hydroxy-N,N-di-n-propyltryptammonium) fumarate tetrahydrate (4-HO-DPT fumarate·4H2O) and to crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride (4-HO-DPT chloride). Compositions containing crystalline 4-HO-DPT fumarate·4H2O or crystalline 4-HO-DPT chloride, and methods of use are disclosed.

## Claims

### Claim 1

Crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride.

### Claim 2 (depends on 1)

A composition comprising crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride according to claim 1 and an excipient.

### Claim 3 (depends on 1)

A composition comprising crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride according to claim 1 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, or (i) a purified hericenone.

### Claim 4 (depends on 1)

A method of treating a psychological disorder selected from post-traumatic stress disorder (PTSD) and depression, the method comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride according to claim 1.

### Claim 5 (depends on 2)

A method of treating a psychological disorder selected from post-traumatic stress disorder (PTSD) and depression, the method comprising the step of:
administering to a subject in need thereof a composition according to claim 2.

### Claim 6 (depends on 3)

A method of treating a psychological disorder selected from post-traumatic stress disorder (PTSD) and depression, the method comprising the step of:
administering to a subject in need thereof a composition according to claim 3.

### Claim 7 (depends on 1)

A method of treating pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride according to claim 1.

### Claim 8 (depends on 2)

A method of treating pain comprising the step of:
administering to a subject in need thereof a composition according to claim 2.

### Claim 9 (depends on 3)

A method of treating pain comprising the step of:
administering to a subject in need thereof a composition according to claim 3.
